Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
China Recombinant Human Thrombopoietin Markets, 2013-2017, 2017-2018 & 2019-2023 | ||
By: PR Newswire Association LLC. - 16 Sep 2019 | Back to overview list |
|
DUBLIN, Sept. 16, 2019 /PRNewswire/ --Recombinant Human Thrombopoietin Market, 2019-2023" report has been added to ResearchAndMarkets.com's offering. The sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China. In 2017, it reached CNY 523 million, representing a CAGR of 27.90% from 2013 to 2017. It is expected that as the number of patients with thrombopenia increases in China, the demand for Recombinant Human Thrombopoietin will also increase. Considering the high growth rate of the Recombinant Human Thrombopoietin market, Recombinant Human Thrombopoietin products by other enterprises will probably be approved to be launched in China in the next few years. In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver diseases and tumor chemotherapy. Thrombopenia may also be congenital or drug-induced. Primary immune thrombopenia is a clinically common hemorrhagic disease, accounting for 1/3 of hemorrhagic diseases. The annual incidence of primary immune thrombopenia is 5/100,000 to 10/100,000. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows that 20% to 30% of patients receiving chemotherapy have obvious thrombopenia. The incidence of thrombopenia is 81.80% among patients receiving single-agent carboplatin chemotherapy, 58.20% among patients receiving carboplatin combination chemotherapy, 64.40% among patients receiving gemcitabine chemotherapy and 59.30% among patients receiving paclitaxel chemotherapy. Key Topics Covered: 1 Relevant Concepts of Recombinant Human Thrombopoietin For more information about this report visit https://www.researchandmarkets.com/r/7dutyp Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets View original content:http://www.prnewswire.com/news-releases/china-recombinant-human-thrombopoietin-markets-2013-2017-2017-2018--2019-2023-300918824.html SOURCE Research and Markets |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |